IP Library Granted Patent US 11,299,766
Granted Patent B2
US 11,299,766 · App. 16/888,375 · Granted Apr 12, 2022

Multiplex amplification detection assay

Inventors: Graham P. Lidgard (Middleton, WI); Hatim Allawi (Middleton, WI)
Assignee: Exact Sciences Corporation
C12Q1/6806C12N15/1006C12Q1/686C12Q1/6837C12Q2600/154C12Q2600/166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,299,766
App. No.
16/888,375
Granted
Apr 12, 2022
Kind
B2
Abstract

Provided herein is technology relating to the amplification-based detection of bisulfite-treated DNAs and particularly, but not exclusively, to methods and compositions for multiplex amplification of low-level sample DNA prior to further characterization of the sample DNA. The technology further provides methods for isolating DNA from blood or blood product samples, e.g., plasma samples.

Claims (26)

1. A method of analyzing a sample for multiple target nucleic acids in a PCR-flap assay, comprising:

a) providing a sample comprising DNA suspected of containing one or more of a plurality of different target regions;

b) treating the sample in an amplification reaction mixture comprising a PCR-flap assay buffer comprising 6 to 10 mM Mg′ under conditions wherein the different target regions, if present in the sample, are amplified to form a pre-amplified mixture;

c) partitioning the pre-amplified mixture into a plurality of different PCR-flap assay reaction mixtures comprising the PCR-flap assay buffer; and

d) conducting a plurality of PCR-flap assays with the PCR-flap assay reaction mixtures, wherein the different target regions, if present in the sample at step a), are amplified and detected in the PCR-flap assay reaction mixtures.

2. The method of claim 1 , wherein the DNA is from a human subject.

3. The method of claim 1 , wherein the sample is prepared from a body fluid.

4. The method of claim 1 , wherein the body fluid comprises plasma.

5. The method of claim 1 , wherein the DNA comprises bisulfite-treated DNA.

6. The method of claim 1 , wherein the sample is prepared from cell-free DNA isolated from plasma.

7. The method of claim 1 , wherein the amplification reaction comprises at least 3 different primer pairs for amplifying at least 3 different target regions, if present in the sample.

8. The method of claim 1 , wherein the amplification reaction comprises at least 4 different primer pairs for amplifying at least 4 different target regions, if present in the sample.

9. The method of claim 1 , wherein the pre-amplified mixture is diluted with a diluent prior to partitioning.

10. The method of claim 1 , wherein the amplification reaction mixture and/or the plurality of different PCR-flap assay reaction mixtures comprise bulk fish DNA.

11. The method of claim 1 , wherein the PCR-flap assay reaction mixtures comprise a FEN-1 endonuclease.

12. The method of claim 1 , wherein the PCR-flap assay buffer comprises MgCl 2 .

13. The method of claim 1 , wherein the amplification reaction mixture comprises at least 2 different primer pairs for amplifying the at least 2 different target regions, and wherein each PCR-flap assay reaction mixture comprises an additional amount of a primer pair selected from the at least 2 different primer pairs.

14. The method of claim 13 , wherein each PCR-flap assay reaction mixture further comprises:

i) a flap oligonucleotide, and

ii) a hairpin oligonucleotide comprising a region that is complimentary to a portion of the flap oligonucleotide.

15. The method of claim 1 , wherein the amplification reaction mixture of step b) is exposed to thermal cycling conditions limited to fewer than 20 thermal cycles.

16. The method of claim 15 , wherein the hairpin oligonucleotide comprises a fluorophore moiety.

17. The method of claim 1 , wherein the plurality of different target regions comprises a reference target region.

18. The method of claim 17 , wherein said reference target region comprises β-actin or ZDHHC1.

19. The method of claim 1 , wherein the sample comprises a DNA process control.

20. The method of claim 19 , wherein the DNA process control comprises a zebrafish RASSF1 sequence.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0249) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075288/0393 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: EXACT SCIENCES CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0249 →
MERGER Recorded Jan 14, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 058738/0465 →
Cited By (2)
US 12,297,510 US 12,655,466